BRIEF published on 06/18/2026 at 09:35, 4 months 11 days ago AATec Medical dévoilera les données de l'ATL-105 lors de sa conférence de 2026. ATL-105 Données Précliniques Bronchectasie Traitement Multimodal Essai De Phase 1/2
BRIEF published on 06/18/2026 at 09:35, 4 months 11 days ago AATec Medical to Unveil ATL-105 Data at 2026 Conference Preclinical Data ATL-105 Phase 1/2 Trial Bronchiectasis Multimodal Treatment
PRESS RELEASE published on 06/18/2026 at 09:30, 4 months 11 days ago AATec to Present Data from Lead Candidate ATL-105 at World Bronchiectasis Conference 2026 AATec to present preclinical data on lead candidate ATL-105 at World Bronchiectasis Conference 2026, demonstrating multimodal effects for non-CF bronchiectasis treatment Respiratory Diseases Preclinical Data ATL-105 Bronchiectasis AATec
BRIEF published on 07/15/2025 at 09:05, 1 year 3 months ago AATec Medical et Northway Biotech forment un partenariat pour le développement de la production d'ATL-105 Partenariat ATL-105 Fabrication De Produits Biologiques Maladies Pulmonaires Thérapie Respiratoire
BRIEF published on 07/15/2025 at 09:05, 1 year 3 months ago AATec Medical and Northway Biotech Form Partnership for ATL-105 Production Development Partnership ATL-105 Biologics Manufacturing Lung Diseases Respiratory Therapy
PRESS RELEASE published on 07/15/2025 at 09:00, 1 year 3 months ago AATec Medical and Northway Biotech Announce Partnership to Develop Industrial Production Process for ATL-105 Targeting Lung Diseases AATec Medical and Northway Biotech announce partnership to develop industrial production process for ATL-105 targeting lung diseases Partnership AATec Medical ATL-105 Lung Diseases Northway Biotech
BRIEF published on 04/15/2025 at 11:09, 1 year 6 months ago AATec Medical Secures EUR 4 Million for Respiratory Drug Development Biotechnology Funding Clinical Trials Drug Development Respiratory Diseases
BRIEF published on 04/15/2025 at 11:09, 1 year 6 months ago AATec Medical obtient 4 millions d'euros pour le développement de médicaments respiratoires Biotechnologie Financement Essais Cliniques Développement De Médicaments Maladies Respiratoires
PRESS RELEASE published on 04/15/2025 at 11:04, 1 year 6 months ago AATec Medical Secures EUR 4 Million to Advance Lead Respiratory Drug Candidate to Clinical Development AATec Medical secures EUR 4 million funding to advance lead respiratory drug candidate, ATL-105, for clinical development to treat non-CF bronchiectasis by 2026 Clinical Development AATec Medical Non-CF Bronchiectasis EUR 4 Million Respiratory Drug Candidate
BRIEF published on 09/18/2024 at 10:05, 2 years 1 month ago AATec Medical accueille le professeur James Chalmers au sein de son conseil consultatif scientifique AATec Medical Conseil Consultatif Scientifique James Chalmers Bronchectasie AAT Recombinante
Published on 10/29/2026 at 21:30, 34 minutes ago Shelfie Announces Amendments to Previously Announced Acquisition of Aspect
Published on 10/29/2026 at 18:30, 3 hours 34 minutes ago Kidoz Inc. Appoints Derek Sentner as Chief Revenue Officer
Published on 10/29/2026 at 16:05, 5 hours 59 minutes ago SouthGobi Announces Date of Special Meeting of Shareholders and The Record Date
Published on 10/29/2026 at 13:31, 8 hours 33 minutes ago First Breach Advances Ammunition and Drone Manufacturing Expansion as U.S. Reshoring Accelerates
Published on 10/29/2026 at 21:29, 35 minutes ago 2CRSi SA: Publication of the consolidated annual results and the 2025-2026 Annual Financial Report postponed to 30 October 2026
Published on 10/29/2026 at 21:29, 35 minutes ago 2CRSi SA: Report de la publication des résultats annuels consolidés et du Rapport Financier Annuel 2025-2026 au 30 octobre 2026
Published on 10/29/2026 at 21:20, 44 minutes ago 2CRSi SA: 2CRSi publie les conclusions de l'expert indépendant mandaté à la suite du rapport Grizzly Research et apporte des précisions sur plusieurs communications antérieures
Published on 10/29/2026 at 21:20, 44 minutes ago 2CRSi SA: 2CRSi publishes the conclusions of the independent expert appointed following the Grizzly Research report and provides clarifications on several previous communications
Published on 10/29/2026 at 20:13, 1 hour 51 minutes ago Interim individual financial statements of Sirma Group JSC for the period ending on September 30, 2026
Published on 10/29/2026 at 18:02, 4 hours 2 minutes ago TF1 9M 2026 results - Consolidated financial statements and appendix
Published on 10/29/2026 at 18:02, 4 hours 2 minutes ago Résultats TF1 9M 2026 - Comptes consolidés et annexes aux comptes
Published on 10/29/2026 at 18:00, 4 hours 4 minutes ago GUILLEMOT CORPORATION: THIRD-QUARTER 2026 TURNOVER / Successful new product launches and acceleration of international commercial partnerships
Published on 10/29/2026 at 18:00, 4 hours 4 minutes ago GUILLEMOT CORPORATION : CHIFFRE D’AFFAIRES TROISIEME TRIMESTRE 2026 / Succès des nouveaux lancements et accélération des partenariats commerciaux internationaux
